[Marcel Fratzscher] EU must revive multilateralism

US President Donald Trump's misguided trade war against the rest of the world could mark the beginning of the end for both his political dominance and his 'Make America Great Again' movement -- but only if Germany and Europe can coordinate a powerful international response.
The European Commission and the outgoing German government's biggest mistake was to signal a willingness to concede to Trump's demands, potentially turning his economic blunder into a political victory. It should be clear by now that appeasing Trump will only hasten the collapse of the multilateral trading system and further undermine democratic governance worldwide.
The European Union's response will be pivotal in determining whether the Trump administration (which is intent on dismantling the multilateral trading order) or China (which seeks to preserve it) will prevail. European leaders face a clear choice: stand for multilateralism and align with China or side with Trump's MAGA-fied United States. There is no third option.
Germany and Europe cannot remain neutral in this conflict. Giving in to Trump's demands by pursuing a bilateral trade agreement would be tantamount to endorsing the end of multilateralism.
The EU's ongoing failure to push back against Trump's policies reflects shocking shortsightedness and political naivete. While the direct economic impact of Trump's tariffs on Europe will likely be limited, the long-term consequences -- especially for Germany's export-driven economic model -- could be dire. Yielding to Trump would threaten the very foundation of German prosperity, which depends more than that of any other European country on open global trade grounded in non-discrimination, fairness, and competition.
So, how should Germany and the EU respond to Trump's tariffs? The incoming German government -- together with France, the United Kingdom and other European partners -- must defend multilateralism by aligning with China and imposing reciprocal tariffs on American goods.
In future negotiations with the US, European leaders must also insist on two key conditions. First, they should call for a renewed commitment to multilateralism as the foundation of the global trade system. That includes not only rolling back tariffs and other trade barriers to pre-crisis levels, but also revitalizing multilateral institutions like the World Trade Organization, which the US has systematically undermined by blocking the appointment of new judges to its appellate body.
Importantly, the focus should not be limited to the WTO. Other multilateral institutions such as the United Nations, the International Monetary Fund, and the World Bank must also be empowered to play a more active role, particularly in representing and protecting the interests of the weakest economies in the Global South.
Second, Europe should push for fair competition and common rules, especially when it comes to regulating US-based tech giants. These companies pay little to no tax and routinely violate EU laws and regulations concerning data protection, ethical standards and market competition.
The recent US court ruling that Google has indeed built an illegal monopoly in search underscores the urgency of the issue. As German Finance Minister Jorg Kukies recently observed, European countries are increasingly reliant on services provided by US tech giants. If the EU fails to act now, this harmful dependence will continue to deepen, making Europe even more vulnerable to Trump-style political and commercial blackmail.
Reviving multilateralism will also require meaningful concessions and reforms from China, the EU and Germany to help correct global imbalances. Through massive subsidies and other forms of support for domestic firms, China has repeatedly undermined multilateral rules to gain unfair advantages. But Germany also must reduce its own gigantic current account surpluses, which are largely driven by domestic regulations and other structural barriers that make it harder for foreign companies to enter its market.
Given that addressing these distortions could offer considerable benefits to American companies, there is good reason to believe that such a balanced trade agreement might appeal to Trump and encourage him to change course.
Despite its economic costs, Trump's global tariff war offers Europe a chance to establish itself as a mediator and defender of multilateralism in an increasingly multipolar world. It is high time that Europe stood up for its values and coordinated a unified response with partners like China, Canada, Mexico, the UK and Japan.
By provoking a confrontation with all the world's major economies at once, Trump has made a serious strategic miscalculation. Pushing back may cost Europe in the short term, but allowing Trump to prevail and dismantle the multilateral trading system would be far more damaging -- both to the EU economy and to democracy itself.
Marcel Fratzscher, a former senior manager at the European Central Bank, is President of the think tank DIW Berlin and Professor of Macroeconomics and Finance at Humboldt University of Berlin. The views expressed here are the writer's own. -- Ed.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Korea Herald

4 hours ago

• Korea Herald

Pentagon: 14 bunker busters used in attacks on Iranian nuclear sites

The US military used 14 GBU-57 bunker-busting bombs in its overnight attacks on key Iranian nuclear sites, the Pentagon said on Sunday. The powerful bombs were dropped on two nuclear facilities, Chairman of the Joint Chiefs of Staff Dan Caine said during a press conference, hours after the US intervened in the conflict against Iran on behalf of Israel. It comes after US President Donald Trump said US aircraft attacked three nuclear sites in Iran overnight, including Natanz, Isfahan and the Fordow uranium enrichment facility - widely believed to be one of Israel's most critical war targets. The move marks a serious escalation in the war between Israel and Iran, amid already heightened fears of a wider regional conflict. Iran has said the US intervention will lead to "everlasting consequences," amid concern that Iran might retaliate by targeting US bases in the region. Israel launched widespread airstrikes across Iran on June 13, saying it is aimed at preventing Iran from developing a nuclear weapon - a charge that Tehran has consistently denied. (DPA)

Korea Herald

5 hours ago

• Korea Herald

US says Iran nuclear program 'devastated', no push for regime change

The US defense chief said Sunday that strikes ordered by President Donald Trump overnight had "devastated" Iran's nuclear program and urged Iranian leaders to seek peace to avoid further attacks. "We devastated the Iranian nuclear program," Defense Secretary Pete Hegseth told a Pentagon press briefing, adding that the operation "did not target Iranian troops or the Iranian people." Trump "seeks peace, and Iran should take that path," Hegseth said. "This mission was not, and has not, been about regime change," he added. "The president authorized a precision operation to neutralize the threats to our national interests posed by the Iranian nuclear program and the collective self-defense of our troops and our ally Israel. (AFP)

Korea Herald

9 hours ago

• Korea Herald

[Bio USA] SK Biopharmaceuticals CEO highlights resilience, open innovation amid global shifts

Korea Herald correspondent BOSTON — SK Biopharmaceuticals CEO Lee Dong-hoon underscored the company's preparedness for potential US tariff changes and emphasized the critical role of open innovation in shaping the future of global pharmaceuticals. 'We've weathered volatility in our share price over the past year, but the impact of potential price cuts has been minimal,' Lee said Thursday during a press conference on the sidelines of the 2025 Bio USA. 'Our direct-to-market sales model remains fundamentally solid.' He recalled a particularly tense moment earlier this year when shifting US tariff policies posed logistical challenges. In April, the company rushed to transport finished products from Canada into the US before a new tariff deadline. 'When the final truck finally cleared customs, everyone burst into applause,' he recounted. To prevent such risks from recurring, the company now assembles finished products in Canada and ensures shipments cross the border ahead of any policy changes. Looking ahead, SK Biopharmaceuticals is evaluating Puerto Rico as a potential US-based manufacturing site, leveraging its status as a US territory and pharmaceutical hub. 'Canada is cost-effective for now, but we're preparing for every scenario,' Lee said, noting the company's tariff risk is now 'close to zero' for the year. Lee also expressed confidence in the company's long-term growth. 'We've already announced our goal to hit 1 trillion won ($728 million) in sales by 2029, and we're on track,' he said, citing consistent profitability since last year. A cornerstone of SK Biopharmaceuticals' strategy is open innovation. Instead of relying solely on internal research and development, the company is partnering with universities, biotech firms and research institutions. 'Major global pharmaceutical firms are moving away from in-house basic research, and so are we. When you can collaborate and generate results at a fraction of the cost, your possibilities expand," he explained. The CEO emphasized the importance of tapping into underutilized technologies at US universities and biotech startups to diversify the company's pipeline, moving beyond its core focus on epilepsy into areas like oncology. Artificial intelligence is another major focus area. Lee highlighted the company's work on EEG-based seizure prediction models in collaboration with European and South American partners, along with AI algorithm development trials currently underway in Korea. 'AI is no longer optional. It's essential in every part of the business,' he said. One standout partnership is with PhnyX Lab, whose AI-driven automation of clinical documentation significantly reduced paperwork. 'Even our US team, which was initially skeptical, was blown away,' Lee said, calling the shift 'Copernican' in scale for how it will reduce time and cost. The CEO also outlined plans to build a global digital platform for epilepsy patients — a space where patients and physicians can share experiences and insights. 'It's not about selling drugs,' he clarified. 'It's about collecting data to inform AI-powered marketing, drug development and clinical trial design.' The company is looking three to five years ahead, aiming to build an ecosystem where shared data drives innovation across functions. In the US, SK Biopharmaceuticals is intensifying its engagement with health care providers. Lee has personally met with dozens of physicians this year, aiming for 100 meetings, to gather insights that will shape lifecycle strategies such as patent extensions, expanded indications and new formulations like IV delivery. Meanwhile, SK Biopharmaceuticals has invested in targeted TV and YouTube campaigns for its flagship epilepsy drug, Xcopri (cenobamate). Its 'Road to Reduction' campaign drew 9.37 million views in just one month, signaling the brand's growing visibility and leadership in the epilepsy treatment market.